1. Home
  2. FRLN

FRLN

Freeline Therapeutics Holdings plc

Logo Freeline Therapeutics Holdings plc

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

0

Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.

Founded: 2015 Country:
United Kingdom
United Kingdom
Employees: 152 City: N/A
Market Cap: 28.2M IPO Year: 2020
Target Price: $5.17 AVG Volume (30 days): 27.6K
Analyst Decision: Hold Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -11.40 EPS Growth: N/A
52 Week Low/High: $2.11 - $8.70 Next Earning Date: 04-02-2024
Revenue: $622,000 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: